AnaptysBio - Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Listen to Short Takes on Deep Science
Anaptys Publications and Relevant Literature
Pipeline
Overview
Rosnilimab
ANB033
ANB101
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
See Where We Work
Total Rewards Program Highlights
Get to Know Our Team
Join Team Anaptys!
Contact
Toggle
Home
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
June 2, 2023
Warren et al., 2023